Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead's CAR-T Therapy Yescarta Slowly Getting Off The Ground

Executive Summary

Slow and steady approach to launch should position Yescarta well in the long run, Gilead maintains – the CAR-T therapy brought in $7m in its first month. But Gilead is still suffering from the decline in hepatitis C.


Related Content

Pharma Q1 Results Preview: Merck & Co, Pfizer, Gilead, Novo Nordisk, Teva, Celgene
HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last
HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End
Gilead's R&D Leadership Change Is End Of Bischofberger Era
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Gilead Acquisition Of Cell Design: The Next Logical Step
Gilead Says 16 Cancer Centers Getting Ready To Administer Yescarta
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
What's Gilead Getting From Kite For Nearly $12bn?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts